332 related articles for article (PubMed ID: 33085777)
1. A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Ferreri AJM; Cattaneo C; Lleshi A; Verga L; Allione B; Facchetti F; Ponzoni M; Foppoli M; Ferrari D; Rigacci L; Pecciarini L; Donadoni G; Fumagalli L; Sassone M; Calimeri T; Rossi G; Spina M; Re A
Br J Haematol; 2021 Jan; 192(1):119-128. PubMed ID: 33085777
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Ferreri AJM; Angelillo P; Erbella F; Cattaneo C; Verga L; Lleshi A; Allione B; Ponzoni M; Facchetti F; Pagani C; Foppoli M; Pecciarini L; Sassone M; Steffanoni S; Flospergher E; Rossi G; Spina M; Re A
Blood Adv; 2022 Nov; 6(22):5811-5820. PubMed ID: 35580327
[TBL] [Abstract][Full Text] [Related]
3. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
9. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
[TBL] [Abstract][Full Text] [Related]
10. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Decaudin D; Mounier N; Tilly H; Ribrag V; Ghesquières H; Bouabdallah K; Morschhauser F; Coiffier B; Le Gouill S; Bologna S; Delarue R; Huynh A; Bosly A; Brière J; Gisselbrecht C
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):212-8. PubMed ID: 21575926
[TBL] [Abstract][Full Text] [Related]
11. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
12. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Martin N; Borchiellini D; Coso D; Gastaud L; Boscagli A; Saudes L; Re D; Gutnecht J; Garnier G; Petit E; Barriere J; Naman H; Rossignol B; Thyss A; Peyrade F
Leuk Lymphoma; 2015; 56(8):2379-87. PubMed ID: 25563428
[TBL] [Abstract][Full Text] [Related]
14.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
15. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Schmitz N; Pfistner B; Sextro M; Sieber M; Carella AM; Haenel M; Boissevain F; Zschaber R; Müller P; Kirchner H; Lohri A; Decker S; Koch B; Hasenclever D; Goldstone AH; Diehl V; ;
Lancet; 2002 Jun; 359(9323):2065-71. PubMed ID: 12086759
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
[TBL] [Abstract][Full Text] [Related]
18. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
van Imhoff GW; van der Holt B; MacKenzie MA; Ossenkoppele GJ; Wijermans PW; Kramer MH; van 't Veer MB; Schouten HC; van Marwijk Kooy M; van Oers MH; Raemaekers JM; Sonneveld P; Meulendijks LA; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
Leukemia; 2005 Jun; 19(6):945-52. PubMed ID: 15800666
[TBL] [Abstract][Full Text] [Related]
19. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Wu R; Ma L
Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
[TBL] [Abstract][Full Text] [Related]
20. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
